ARGX vs. PFE: argenx vs. Pfizer Stock Comparison

Company Profile

argenx (ARGX) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while PFE is classified in Pharmaceuticals.

Pfizer (PFE) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas argenx (ARGX) sees a more moderate 359.84K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Pfizer (PFE) earns 4.47% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

argenx (ARGX) at 31.73% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

Both argenx (ARGX) at 36.27% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Pfizer (PFE) at -1.65% is in the bottom quartile, showing a clear gap in revenue momentum.

Both argenx (ARGX) at 53.13% and Pfizer (PFE) at -3.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Pfizer (PFE) shows current ratio of 1.42 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Pfizer (PFE) at 0.71 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; argenx (ARGX) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both argenx (ARGX) at 32.12 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while argenx (ARGX) at 9.86 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

Pfizer (PFE) at 1.88 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.

Valuation Metrics